These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 28692448

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K, Van Stappen T, Jairath V, Gecse K, Khanna R, D'Haens G, Vermeire S, Gils A, Feagan BG, Levesque BG, Vande Casteele N.
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [Abstract] [Full Text] [Related]

  • 3. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
    Smits LJ, Derikx LA, de Jong DJ, Boshuizen RS, van Esch AA, Drenth JP, Hoentjen F.
    J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S, Heap GA, Ahmad T, Kim H, Kwon T, Chowers Y.
    Expert Rev Gastroenterol Hepatol; 2015 Nov; 9 Suppl 1():27-34. PubMed ID: 26395532
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L, Peyrin-Biroulet L.
    Curr Med Chem; 2019 Nov; 26(2):270-279. PubMed ID: 27758715
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
    Radin M, Sciascia S, Roccatello D, Cuadrado MJ.
    BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
    [Abstract] [Full Text] [Related]

  • 12. Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples.
    Gils A, Van Stappen T, Dreesen E, Storme R, Vermeire S, Declerck PJ.
    Inflamm Bowel Dis; 2016 Apr; 22(4):969-75. PubMed ID: 26954707
    [Abstract] [Full Text] [Related]

  • 13. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
    Eberl A, Huoponen S, Pahikkala T, Blom M, Arkkila P, Sipponen T.
    Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
    [Abstract] [Full Text] [Related]

  • 14. Biosimilars in inflammatory bowel disease: ready for prime time?
    Gomollón F.
    Curr Opin Gastroenterol; 2015 Jul; 31(4):290-5. PubMed ID: 26039720
    [Abstract] [Full Text] [Related]

  • 15. Experience with Biosimilar Infliximab (Remsima®) in Norway.
    Jahnsen J, Kaasen Jørgensen K.
    Dig Dis; 2017 Jul; 35(1-2):83-90. PubMed ID: 28147374
    [Abstract] [Full Text] [Related]

  • 16. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
    Ben-Horin S, Vande Casteele N, Schreiber S, Lakatos PL.
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1685-1696. PubMed ID: 27215364
    [Abstract] [Full Text] [Related]

  • 17. Switching From Originator to Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease Is Feasible and Uneventful.
    Gervais L, McLean LL, Wilson ML, Cameron C, Curtis L, Garrick V, Armstrong K, Tayler R, Henderson P, Hansen R, Chalmers I, Wilson DC, Russell RK.
    J Pediatr Gastroenterol Nutr; 2018 Dec; 67(6):745-748. PubMed ID: 29985877
    [Abstract] [Full Text] [Related]

  • 18. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, Kim HK, Cheon JH, Im JP, Kim YS, Lee SY, Lee SJ.
    Expert Rev Gastroenterol Hepatol; 2015 Dec; 9 Suppl 1():35-44. PubMed ID: 26395533
    [Abstract] [Full Text] [Related]

  • 19. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
    Blair HA, Deeks ED.
    BioDrugs; 2016 Oct; 30(5):469-480. PubMed ID: 27650650
    [Abstract] [Full Text] [Related]

  • 20. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T, Letkovsky J.
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.